FDA granted accelerated approval to dostarlimab-gxly for dMMR or MSI-H locally advanced rectal cancer based on interim phase 2 AZUR-1 results.
|Articles|November 29, 2013
Supplements and Featured Publications
- A Data-Driven Approach to Improving Clinical and Economic Outcomes in Multiple Sclerosis [CME/CNE/CP
- Volume 19
- Issue 16 Suppl
Post Test: A Data-Driven Approach to Improving Clinical and Economic Outcomes in Multiple Sclerosis
Advertisement
Instructions
After reading “A Data-Driven Approach to Improving Clinical and Economic Outcomes in Multiple Sclerosis,” complete the program evaluation and select the single best answer to each of the posttest questions.
Participants must read each article in this supplement, complete the online posttest achieving a passing score of 70% or higher, and complete an online evaluation and request for credit. Detailed instructions on obtaining CE credit are included following the sample online posttest.
Articles in this issue
almost 13 years ago
Managed Care Aspects of Managing Multiple Sclerosisalmost 13 years ago
Management of Multiple Sclerosisalmost 13 years ago
Multiple Sclerosis UpdateAdvertisement
Related to this article
Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.
Nearly 3 in 4 bariatric surgery candidates had clinical obesity, a phenotype that BMI alone did not distinguish from preclinical obesity.
Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.
A review of 47 endometriosis guidelines found most came from high-income settings and diverged on biomarkers, repeat surgery, and fertility referral.
The meeting covered several topics in eye care, including how artificial intelligence (AI) can play a part in eye care.
A meta-analysis of 27 trials found a 15% cardiovascular risk reduction per 10-mm Hg lower systolic BP, with no added risk of kidney failure.
In a Japanese registry of 1235 patients with AMI treated with PCI, Lp(a) of 24 mg/dL or higher independently predicted MACE and HF hospitalization.
Advertisement
Advertisement
Trending on AJMC
1
Pathological Response Does Not Reliably Predict Survival in Sarcoma
2
5 Things to Know About the One Big Beautiful Bill Act
3
New CHEST Guidelines Offer a Road Map for Bronchiectasis
4
CHEST Investigations Explore COPD Guideline Adherence, Adding Ensifentrine, and Use of AI in Education
5